Suppr超能文献

COVID-19 患者在进行慢性血液透析和腹膜透析治疗的临床结果。

Clinical outcomes of COVID-19 in patients undergoing chronic hemodialysis and peritoneal dialysis.

机构信息

Hospital de Base de São José do Rio Preto, Faculdade de Medicina de São José do Rio Preto, Divisão de Nefrologia, São José do Rio Preto, SP, Brasil.

Faculdade de Medicina de São José do Rio Preto, Laboratório de Imunologia e Transplante Experimental, São José do Rio Preto, SP, Brasil.

出版信息

J Bras Nefrol. 2022 Oct-Dec;44(4):505-510. doi: 10.1590/2175-8239-JBN-2021-0261en.

Abstract

BACKGROUND

The reported incidence and fatality rate of the severe acute respiratory syndrome coronavirus 2 in patients receiving chronic dialysis are higher than in the general population. We sought to study the outcomes following coronavirus disease 2019 (COVID-19) diagnosis in patients undergoing chronic hemodialysis (HD) or peritoneal dialysis (PD) in a single center in Brazil.

METHODS

Of the 522 patients on dialysis evaluated between March 1, 2020, and October 1, 2021, those presenting symptoms or with a history of close contact with COVID-19 patients were tested with reverse-transcription polymerase chain reaction of samples from nasopharyngeal swabs.

RESULTS

Of the 522 patients, 120 were positive for COVID-19 infection, of which 86% were on HD and 14% in the PD program. The incidence per 10,000 inhabitants was higher in the HD group than in the PD group (2,423.5 vs. 1,752.5). The mortality per 10,000 inhabitants (470.5 vs. 927.8) and the fatality rate (19.4 vs. 52.9%, p = 0.005) were higher in the PD group. The PD group also had a higher need for hospitalization, intensive care, and mechanical ventilation.

CONCLUSIONS

We advise caution when considering strategies to transfer patients from HD to the PD program to minimize the risk of COVID-19 for patients on HD.

摘要

背景

在接受慢性透析的患者中,严重急性呼吸综合征冠状病毒 2 的报告发病率和病死率高于普通人群。我们旨在研究巴西一家单一中心接受慢性血液透析(HD)或腹膜透析(PD)的患者在诊断出 2019 年冠状病毒病(COVID-19)后的结局。

方法

在 2020 年 3 月 1 日至 2021 年 10 月 1 日期间评估的 522 名透析患者中,出现症状或与 COVID-19 患者有密切接触史的患者用鼻咽拭子样本进行逆转录聚合酶链反应检测。

结果

在 522 名患者中,有 120 名 COVID-19 感染阳性,其中 86%接受 HD,14%接受 PD 治疗。每 10000 名居民的发病率在 HD 组高于 PD 组(2423.5 比 1752.5)。每 10000 名居民的死亡率(470.5 比 927.8)和病死率(19.4 比 52.9%,p = 0.005)在 PD 组更高。PD 组还需要更高的住院、重症监护和机械通气。

结论

我们建议在考虑将患者从 HD 转移到 PD 方案的策略时要谨慎,以最大程度地降低 HD 患者 COVID-19 的风险。

相似文献

10
[REIN Report 2011--summary].[2011年肾脏疾病改善全球结果(KDIGO)报告——摘要]
Nephrol Ther. 2013 Sep;9 Suppl 1:S3-6. doi: 10.1016/S1769-7255(13)70036-1.

本文引用的文献

3
Presence of SARS-CoV-2 Antibodies in Spent Peritoneal Dialysate.新冠病毒抗体在腹膜透析废液中的存在情况。
J Am Soc Nephrol. 2021 Aug;32(8):1865-1867. doi: 10.1681/ASN.2021020161. Epub 2021 Jul 6.
6
Initial Effects of COVID-19 on Patients with ESKD.COVID-19 对 ESKD 患者的初始影响。
J Am Soc Nephrol. 2021 Jun 1;32(6):1444-1453. doi: 10.1681/ASN.2021010009. Epub 2021 Apr 8.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验